These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 30646077)
1. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers. Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077 [TBL] [Abstract][Full Text] [Related]
2. Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers. Heyward J; Jones CM; Compton WM; Lin DH; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket MC; Porter L; Tierce JC; Alexander GC JAMA Netw Open; 2018 Oct; 1(6):e183044. PubMed ID: 30646222 [TBL] [Abstract][Full Text] [Related]
3. Association of Formulary Exclusions and Restrictions for Opioid Alternatives With Opioid Prescribing Among Medicare Beneficiaries. Rao T; Kiptanui Z; Dowell P; Triebwasser C; Alexander GC; Harris I JAMA Netw Open; 2020 Mar; 3(3):e200274. PubMed ID: 32119095 [TBL] [Abstract][Full Text] [Related]
4. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval. Shaw DL; Dhruva SS; Ross JS J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of Nonopioid and Opioid Prescriptions Among Commercially Insured Patients with Chronic Pain. Miller GF; Guy GP; Zhang K; Mikosz CA; Xu L Pain Med; 2019 Oct; 20(10):1948-1954. PubMed ID: 30481359 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance. DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016 [TBL] [Abstract][Full Text] [Related]
7. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans. Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008 [TBL] [Abstract][Full Text] [Related]
8. Differences in Diabetic Prescription Drug Utilization and Costs Among Patients With Diabetes Enrolled in Colorado Marketplace and Medicaid Plans, 2014-2015. Khorrami P; Sinha MS; Bhanja A; Allen HL; Kesselheim AS; Sommers BD JAMA Netw Open; 2022 Jan; 5(1):e2140371. PubMed ID: 35029667 [TBL] [Abstract][Full Text] [Related]
9. Coverage of New Drugs in Medicare Part D. Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786 [TBL] [Abstract][Full Text] [Related]
10. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019. Zhou T; Liu P; Dhruva SS; Shah ND; Ramachandran R; Berg KM; Ross JS JAMA Intern Med; 2022 Feb; 182(2):185-195. PubMed ID: 34982097 [TBL] [Abstract][Full Text] [Related]
11. Medicare Part D Coverage Restrictions and Patient Cost-Sharing for Opioids Commonly Used for Cancer Pain, 2015-2021. Bao Y; Zhang H; Hartung DM; Witkin LR; Paice JA JCO Oncol Pract; 2022 Oct; 18(10):e1574-e1586. PubMed ID: 35797497 [TBL] [Abstract][Full Text] [Related]
12. Federal and Statewide Coverage for Opioid-Sparing Chronic Pain Treatments. McKay M; Gorvine MM; Zaller N; Singh V; Goree J Pain Physician; 2022 Dec; 25(9):E1457-E1466. PubMed ID: 36608017 [TBL] [Abstract][Full Text] [Related]
13. Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population. Ferries E; Racsa P; Bizzell B; Rhodes C; Suehs B J Manag Care Spec Pharm; 2021 May; 27(5):596-606. PubMed ID: 33908274 [No Abstract] [Full Text] [Related]
14. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D. Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105 [TBL] [Abstract][Full Text] [Related]
15. Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21. Andraka-Christou B; Simon KI; Bradford WD; Nguyen T Health Aff (Millwood); 2023 May; 42(5):658-664. PubMed ID: 37126752 [TBL] [Abstract][Full Text] [Related]
16. How does drug coverage vary by insurance type? Analysis of drug formularies in the United States. Régnier SA Am J Manag Care; 2014 Apr; 20(4):322-31. PubMed ID: 24884863 [TBL] [Abstract][Full Text] [Related]
17. Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans. Hodgkin D; Horgan CM; Quinn AE; Merrick EL; Stewart MT; Leslie LK Clin Ther; 2014 Dec; 36(12):2034-2046. PubMed ID: 25450473 [TBL] [Abstract][Full Text] [Related]
18. Medicare program; Medicare prescription drug benefit. Final rule. Centers for Medicare & Medicaid Services (CMS), HHS Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603 [TBL] [Abstract][Full Text] [Related]
19. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017. Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594 [TBL] [Abstract][Full Text] [Related]
20. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab. Socal MP; Ezebilo I; Bai G; Anderson GF Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]